Habenicht U F, Tunn U W, Senge T, Schröder F H, Schweikert H U, Bartsch G, el Etreby M F
Research Laboratories of Schering AG, Berlin, Germany.
J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):557-63. doi: 10.1016/0960-0760(93)90259-y.
The pathogenesis of human benign prostatic hyperplasia (BPH) has not been fully elucidated. There is, however, evidence that estrogens--besides other factors--might play an important role for the growth of the prostate. Consequently, estrogen deprivation might be a new, useful principle for a conservative treatment of BPH. Atamestane, a new, highly selective steroidal aromatase inhibitor has been proven to be successful in antagonizing experimentally-induced estrogen-related stromal overgrowth of the prostate in dogs and monkeys. Double-blind placebo controlled studies are now underway in Europe and the U.S.A. It is anticipated that these studies will give us a definite answer of the clinical validity of this concept in BPH patients in the near future. However, it is very important to take into consideration that for an effective treatment of BPH, a reduction of both the glandular and stromal elements has to be achieved. In other words, both androgens and estrogens seem to be involved in the regulation of (over)growth of the prostate. Therefore, a combination of an androgen and estrogen deprivation might be a more promising approach than any single treatment.
人类良性前列腺增生（BPH）的发病机制尚未完全阐明。然而，有证据表明，除其他因素外，雌激素可能在前列腺生长中起重要作用。因此，雌激素剥夺可能是BPH保守治疗的一种新的有效原则。阿那曲唑，一种新型、高选择性甾体芳香化酶抑制剂，已被证明能成功对抗实验诱导的犬和猴前列腺雌激素相关基质过度生长。目前欧洲和美国正在进行双盲安慰剂对照研究。预计这些研究将在不久的将来为我们提供这一概念在BPH患者中临床有效性的明确答案。然而，必须考虑到，为了有效治疗BPH，必须减少腺体和基质成分。换句话说，雄激素和雌激素似乎都参与了前列腺（过度）生长的调节。因此，雄激素和雌激素剥夺联合治疗可能比任何单一治疗方法更有前景。
